| abstract |
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 is H, C¿1?-C4 alkyl, CN or CONR?4R5; R2 is C¿2-C4 alkyl; R3 is SO¿2?NR?6R7, NO¿2, NH2, NHCOR8, NHSO¿2R?8 or N(SO¿2R?8)2; R?4 and R5¿ are each independently selected from H and C¿1?-C4 alkyl; R?6 and R7¿ are each independently selected from H and C¿1?-C4 alkyl optionally substituted with CO2R?9¿, OH, pyridyl, 5-isoxazolin-3-onyl, morpholino or 1-imidazolidin-2-onyl; or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 1-pyrazolyl or 4-(NR10)-1 piperazinyl group wherein any of said groups may optionally be substituted with one or two substituents selected from C¿1?-C4 alkyl, CO2R?9, NH¿2 and OH; R8 is C1-C4 alkyl or pyridyl; R9 is H or C¿1?-C4 alkyl; and R?10¿ is H, C¿1?-C4 alkyl or (hydroxy)C2-C3 alkyl; are selective cGMP PDE inhibitors useful in the treatment of, inter alia, cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis. |